The reasons include treatment failure, clinical progression/hospitalization, Dabrafenib supplier patient decision/request, compliance difficulties, drug interaction, adverse event and other. Follow-up was censored at the date of treatment change or the last clinical visit. Time to treatment modification was determined by univariate and multivariate survival analysis methods (Kaplan–Meier and Cox proportional hazards models). Predictors associated with modification after treatment failure were assessed using multivariate Cox proportional hazards models with a forward stepwise approach. The final multivariate model was stratified by site and included only covariates that remained

significant at the 0.05 level (two-sided). selleck chemical Nonsignificant variables were presented and adjusted for final multivariate models. Analysis was performed using the statistical package stata 10 for Windows (StataCorp, College Station, TX). Up to March 2007, there were 2446 TAHOD patients who were treatment-naïve and initiated combination antiretroviral therapy (cART) regimens after 1996. There were 16 patients who died after treatment initiation and before a treatment failure was identified; of these,

five patients died from AIDS-related causes, seven from non-AIDS-related causes and four from unknown causes. The median treatment period was 1.97 years [interquartile range (IQR) 0.75–3.55 years]. During the treatment period, the median number of CD4 tests was 4 (IQR 2–8), the median interval between each CD4 test was 147 days (IQR 105–200 days), the median number of

HIV viral load tests was also 4 (IQR 2–7), and the median interval between each viral load test was 168 days (IQR 112–231 days). The proportion of patients having four or more CD4 tests and/or viral tests varied considerably across the TAHOD sites (from <10% to over 80%). A total of 447 patients were identified with at least one type of treatment failure [Table 1; rate of treatment failure 7.85 per 100 person-years; 95% confidence interval (CI) 7.15–8.61]. There were 277 patients with immunological failure (after 6 months of therapy, 151 with a CD4 cell count below the pretreatment level; 157 with a 50% decline from the on-treatment peak CD4 cell count; and 36 with three consecutive Vildagliptin CD4 counts below 100 cells/μL), 158 patients with virological failure (>10 000 copies/mL after 6 months of therapy), and 116 patients with an AIDS-defining illness diagnosed after 6 months of therapy. For a patient with multiple documented failures, the earliest failure was identified for analysis in this paper (242 with immunological failure, 112 with virological failure and 93 with disease progression; a total of 447 patients). Following treatment failure, a total of 253 patients had a treatment modification after failure, of whom 44 had their treatment modified on the same day on which treatment failure was identified. During a median follow-up time of 0.64 years (IQR 0.15–1.